Validated using a knockout cell line

Recombinant Anti-Brd4 antibody [EPR5150(2)] (ab128874)

Knockout Tested Rabbit recombinant monoclonal Brd4 antibody [EPR5150(2)]. Validated in WB, IP, IHC, Flow Cyt, ICC/IF and tested in Mouse, Rat, Human. Cited in 36 publication(s).

Publishing research using ab128874? Please let us know so that we can cite the reference in this datasheet.

ab128874 has been referenced in 50 publications.

  • Fan P  et al. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. J Exp Clin Cancer Res 38:47 (2019). PubMed: 30709380
  • Huang YH  et al. MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation. Int J Med Sci 16:212-220 (2019). PubMed: 30745801
  • Hong Z  et al. KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN. Biomed Pharmacother 114:108793 (2019). PubMed: 30921702
  • Zhang X  et al. BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. Breast Cancer Res 21:51 (2019). PubMed: 30995943
  • Liu H  et al. Inhibition of Brd4 alleviates renal ischemia/reperfusion injury-induced apoptosis and endoplasmic reticulum stress by blocking FoxO4-mediated oxidative stress. Redox Biol 24:101195 (2019). PubMed: 31004990
  • Chaytor L  et al. The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer. Mol Cancer Res 17:1264-1278 (2019). PubMed: 30833300
  • Leonard B  et al. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res 78:4331-4343 (2018). PubMed: 29792310
  • Rhyasen GW  et al. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826 (2018). PubMed: 30036377
  • Jin X  et al. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. Mol Cell 71:592-605.e4 (2018). PubMed: 30057199
  • Ebine K  et al. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells. Sci Rep 8:13225 (2018). PubMed: 30185888
  • Wang B  et al. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 37:224 (2018). PubMed: 30201002
  • Lu G  et al. UBE2G1 governs the destruction of cereblon neomorphic substrates. Elife 7:N/A (2018). PubMed: 30234487
  • Tan Y  et al. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression. Int J Oncol 53:2503-2517 (2018). PubMed: 30272279
  • Li X  et al. BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. Cell Rep 22:796-808 (2018). PubMed: 29346775
  • Gohda J  et al. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1. Sci Rep 8:3521 (2018). PubMed: 29476067
  • Du Z  et al. Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells. Int J Oncol N/A:N/A (2018). PubMed: 29568956
  • DeMars KM  et al. Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia. Biochem Biophys Res Commun 497:410-415 (2018). WB . PubMed: 29448097
  • Vo BT  et al. Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep 8:8733 (2018). WB ; Mouse . PubMed: 29880921
  • Sakaguchi T  et al. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. Oncotarget 9:23003-23017 (2018). PubMed: 29796168
  • Chan KH  et al. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Med Chem 61:504-513 (2018). PubMed: 28595007
  • Lv B  et al. Enhancement of adenovirus infection and adenoviral vector-mediated gene delivery by bromodomain inhibitor JQ1. Sci Rep 8:11554 (2018). PubMed: 30068949
  • Wang Q  et al. Function of BRD4 in the pathogenesis of high glucose-induced cardiac hypertrophy. Mol Med Rep N/A:N/A (2018). PubMed: 30483785
  • Song S  et al. Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-ß-induced endothelial-mesenchymal transition and cardiac fibrosis. J Mol Cell Cardiol 127:83-96 (2018). PubMed: 30529267
  • Tzelepis K  et al. SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nat Commun 9:5378 (2018). PubMed: 30568163
  • Gadd MS  et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 13:514-521 (2017). PubMed: 28288108
  • Wu X  et al. Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma. Cell Physiol Biochem 41:1947-1956 (2017). PubMed: 28391274
  • Meloche J  et al. Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol 37:1513-1523 (2017). PubMed: 28473439
  • Leestemaker Y  et al. Proteasome Activation by Small Molecules. Cell Chem Biol 24:725-736.e7 (2017). PubMed: 28552582
  • Benito E  et al. The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice. Transl Psychiatry 7:e1239 (2017). WB . PubMed: 28949335
  • Sakamaki JI  et al. Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function. Mol Cell 66:517-532.e9 (2017). PubMed: 28525743
  • Carretta M  et al. BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells. PLoS One 12:e0189102 (2017). PubMed: 29240787
  • Janouskova H  et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med 23:1046-1054 (2017). IHC ; Mouse . PubMed: 28805821
  • Zhang P  et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med 23:1055-1062 (2017). PubMed: 28805822
  • Kumar K  et al. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. JCI Insight 2:e88032 (2017). PubMed: 28194432
  • Hogg SJ  et al. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Rep 18:2162-2174 (2017). ChIP ; Human . PubMed: 28249162
  • Wei W  et al. Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription. Cell Res 27:898-915 (2017). ChIP ; Human . PubMed: 28497810
  • Conrad RJ  et al. The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes. Mol Cell 67:1001-1012.e6 (2017). PubMed: 28844864
  • Ghari F  et al. Citrullination-acetylation interplay guides E2F-1 activity during the inflammatory response. Sci Adv 2:e1501257 (2016). PubMed: 26989780
  • Ren K  et al. An Epigenetic Compound Library Screen Identifies BET Inhibitors That Promote HSV-1 and -2 Replication by Bridging P-TEFb to Viral Gene Promoters through BRD4. PLoS Pathog 12:e1005950 (2016). PubMed: 27764245
  • D'Alesio C  et al. RNAi screens identify CHD4 as an essential gene in breast cancer growth. Oncotarget 7:80901-80915 (2016). WB . PubMed: 27779108
  • Wu X  et al. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer. Mol Cancer Ther 15:1029-42 (2016). PubMed: 26939702
  • Tögel L  et al. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Mol Cancer Ther 15:1217-26 (2016). PubMed: 26983878
  • Stratton MS  et al. Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. Cell Rep 16:1366-1378 (2016). PubMed: 27425608
  • Wang B  et al. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. EBioMedicine 2:1650-61 (2015). PubMed: 26870791
  • Gauson EJ  et al. Evidence supporting a role for TopBP1 and Brd4 in the initiation but not continuation of human papillomavirus 16 E1/E2-mediated DNA replication. J Virol 89:4980-91 (2015). IF . PubMed: 25694599
  • Zhan Y  et al. Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery. Epigenetics Chromatin 8:37 (2015). ICC/IF ; Human . PubMed: 26396593
  • Coudé MM  et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget 6:17698-712 (2015). WB . PubMed: 25989842
  • Sahai V  et al. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther 13:1907-17 (2014). Human . PubMed: 24807963
  • Chang SW  et al. Phosphorylation of HPV-16 E2 at serine 243 enables binding to Brd4 and mitotic chromosomes. PLoS One 9:e110882 (2014). WB, ICC/IF . PubMed: 25340539
  • Kalash R  et al. Differences in irradiated lung gene transcription between fibrosis-prone C57BL/6NHsd and fibrosis-resistant C3H/HeNHsd mice. In Vivo 28:147-71 (0). PubMed: 24632969

For licensing inquiries, please contact

Sign up